A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Patrick A. Ott; Siwen Hu-Lieskovan; Bartosz Chmielowski; Ramaswamy Govindan; Aung Naing; Nina Bhardwaj; Kim Margolin; Mark M. Awad; Matthew D. Hellmann; Jessica J. Lin; Terence Friedlander; Meghan E. Bushway; Kristen N. Balogh; Tracey E. Sciuto; Victoria Kohler; Samantha J. Turnbull; Rana Besada; Riley R. Curran; Benjamin Trapp; Julian Scherer; Asaf Poran; Dewi Harjanto; Dominik Barthelme; Ying Sonia Ting; Jesse Z. Dong; Yvonne Ware; Yuting Huang; Zhengping Huang; Amy Wanamaker; Lisa D. Cleary; Melissa A. Moles; Kelledy Manson; Joel Greshock; Zakaria S. Khondker; Ed Fritsch; Michael S. Rooney; Mark DeMario; Richard B. Gaynor; Lakshmi Srinivasan

doi:10.1016/j.cell.2020.08.053

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Patrick A. Ott
, Siwen Hu-Lieskovan
, Bartosz Chmielowski
, Ramaswamy Govindan
, Aung Naing
, Nina Bhardwaj
, Kim Margolin
, Mark M. Awad
, Matthew D. Hellmann
, Jessica J. Lin
, Terence Friedlander
, Meghan E. Bushway
, Kristen N. Balogh
, Tracey E. Sciuto
, Victoria Kohler
, Samantha J. Turnbull
, Rana Besada
, Riley R. Curran
, Benjamin Trapp
, Julian Scherer

Asaf Poran, Dewi Harjanto, Dominik Barthelme, Ying Sonia Ting, Jesse Z. Dong, Yvonne Ware, Yuting Huang, Zhengping Huang, Amy Wanamaker, Lisa D. Cleary, Melissa A. Moles, Kelledy Manson, Joel Greshock, Zakaria S. Khondker, Ed Fritsch, Michael S. Rooney, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan

Research output: Contribution to journal › Article › peer-review

573 Scopus citations

Abstract

In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients with advanced solid tumors. Vaccine-induced T cells persist over time, exhibit cytotoxic potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses were detected following vaccination.

Original language	English
Pages (from-to)	347-362.e24
Journal	Cell
Volume	183
Issue number	2
DOIs	https://doi.org/10.1016/j.cell.2020.08.053
State	Published - 15 Oct 2020

Keywords

NEO-PV-01
T cell
anti-PD-1
cancer vaccine
checkpoint inhibitor
epitope spread
immunotherapy
metastatic cancer
neoantigen
personalized vaccine

Access to Document

10.1016/j.cell.2020.08.053

Cite this

Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., Friedlander, T., Bushway, M. E., Balogh, K. N., Sciuto, T. E., Kohler, V., Turnbull, S. J., Besada, R., Curran, R. R., Trapp, B., ... Srinivasan, L. (2020). A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell, 183(2), 347-362.e24. https://doi.org/10.1016/j.cell.2020.08.053

@article{8a2a8a1467924408afa97141cb4d0a5c,

title = "A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer",

abstract = "In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients with advanced solid tumors. Vaccine-induced T cells persist over time, exhibit cytotoxic potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses were detected following vaccination.",

keywords = "NEO-PV-01, T cell, anti-PD-1, cancer vaccine, checkpoint inhibitor, epitope spread, immunotherapy, metastatic cancer, neoantigen, personalized vaccine",

author = "Ott, \{Patrick A.\} and Siwen Hu-Lieskovan and Bartosz Chmielowski and Ramaswamy Govindan and Aung Naing and Nina Bhardwaj and Kim Margolin and Awad, \{Mark M.\} and Hellmann, \{Matthew D.\} and Lin, \{Jessica J.\} and Terence Friedlander and Bushway, \{Meghan E.\} and Balogh, \{Kristen N.\} and Sciuto, \{Tracey E.\} and Victoria Kohler and Turnbull, \{Samantha J.\} and Rana Besada and Curran, \{Riley R.\} and Benjamin Trapp and Julian Scherer and Asaf Poran and Dewi Harjanto and Dominik Barthelme and Ting, \{Ying Sonia\} and Dong, \{Jesse Z.\} and Yvonne Ware and Yuting Huang and Zhengping Huang and Amy Wanamaker and Cleary, \{Lisa D.\} and Moles, \{Melissa A.\} and Kelledy Manson and Joel Greshock and Khondker, \{Zakaria S.\} and Ed Fritsch and Rooney, \{Michael S.\} and Mark DeMario and Gaynor, \{Richard B.\} and Lakshmi Srinivasan",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = oct,

day = "15",

doi = "10.1016/j.cell.2020.08.053",

language = "English",

volume = "183",

pages = "347--362.e24",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "2",

}

Ott, PA, Hu-Lieskovan, S, Chmielowski, B, Govindan, R, Naing, A, Bhardwaj, N, Margolin, K, Awad, MM, Hellmann, MD, Lin, JJ, Friedlander, T, Bushway, ME, Balogh, KN, Sciuto, TE, Kohler, V, Turnbull, SJ, Besada, R, Curran, RR, Trapp, B, Scherer, J, Poran, A, Harjanto, D, Barthelme, D, Ting, YS, Dong, JZ, Ware, Y, Huang, Y, Huang, Z, Wanamaker, A, Cleary, LD, Moles, MA, Manson, K, Greshock, J, Khondker, ZS, Fritsch, E, Rooney, MS, DeMario, M, Gaynor, RB & Srinivasan, L 2020, 'A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer', Cell, vol. 183, no. 2, pp. 347-362.e24. https://doi.org/10.1016/j.cell.2020.08.053

TY - JOUR

T1 - A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

AU - Ott, Patrick A.

AU - Hu-Lieskovan, Siwen

AU - Chmielowski, Bartosz

AU - Govindan, Ramaswamy

AU - Naing, Aung

AU - Bhardwaj, Nina

AU - Margolin, Kim

AU - Awad, Mark M.

AU - Hellmann, Matthew D.

AU - Lin, Jessica J.

AU - Friedlander, Terence

AU - Bushway, Meghan E.

AU - Balogh, Kristen N.

AU - Sciuto, Tracey E.

AU - Kohler, Victoria

AU - Turnbull, Samantha J.

AU - Besada, Rana

AU - Curran, Riley R.

AU - Trapp, Benjamin

AU - Scherer, Julian

AU - Poran, Asaf

AU - Harjanto, Dewi

AU - Barthelme, Dominik

AU - Ting, Ying Sonia

AU - Dong, Jesse Z.

AU - Ware, Yvonne

AU - Huang, Yuting

AU - Huang, Zhengping

AU - Wanamaker, Amy

AU - Cleary, Lisa D.

AU - Moles, Melissa A.

AU - Manson, Kelledy

AU - Greshock, Joel

AU - Khondker, Zakaria S.

AU - Fritsch, Ed

AU - Rooney, Michael S.

AU - DeMario, Mark

AU - Gaynor, Richard B.

AU - Srinivasan, Lakshmi

PY - 2020/10/15

Y1 - 2020/10/15

N2 - In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients with advanced solid tumors. Vaccine-induced T cells persist over time, exhibit cytotoxic potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses were detected following vaccination.

AB - In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients with advanced solid tumors. Vaccine-induced T cells persist over time, exhibit cytotoxic potential, and can migrate to tumors. Epitope spread and major pathologic tumor responses were detected following vaccination.

KW - NEO-PV-01

KW - T cell

KW - anti-PD-1

KW - cancer vaccine

KW - checkpoint inhibitor

KW - epitope spread

KW - immunotherapy

KW - metastatic cancer

KW - neoantigen

KW - personalized vaccine

UR - https://www.scopus.com/pages/publications/85092455165

U2 - 10.1016/j.cell.2020.08.053

DO - 10.1016/j.cell.2020.08.053

M3 - Article

C2 - 33064988

AN - SCOPUS:85092455165

SN - 0092-8674

VL - 183

SP - 347-362.e24

JO - Cell

JF - Cell

IS - 2

ER -

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this